12 minute read
Mar. 30, 2024
KT-474: The First Clinically Active Heterobifunctional Degrader Outside Oncology
KT-474
oral IRAK4 degrader Ph. II in AD and HS from SBDD of ligands for CRBN, IRAK4, and linker Nature Medicine, Nov. 2023 Kymera Therapeutics, Watertown, MA
Loading...
